Flowonix Medical Inc. and Connecticut Pain Care Announce the First Implant of the Prometra® II Pump in Danbury, CT

Next-generation Intrathecal Infusion Device Successfully Implanted in Chronic Pain Patient

Nov 02, 2015, 08:03 ET from Flowonix Medical Inc.

MOUNT OLIVE, N.J., Nov. 2, 2015 /PRNewswire/ -- Flowonix Medical, Inc., and Connecticut Pain Care announced today the first Connecticut implant of its Prometra® II intrathecal infusion pump took place on October 9, 2015 in Danbury, CT. The intrathecal infusion device was implanted in a 43-year-old female suffering from severe chronic pain; the patient will be managed by David Kloth, MD, of Connecticut Pain Care following implantation.

"I recommended the Prometra II pump to my patient because of its excellent safety profile, accuracy, and increased life span as compared to other products on the market today," stated Dr. Kloth.

Prometra II builds on the technology of the Prometra family. The most significant new advancement in the Prometra II device is its proprietary flow-activated safety valve or FAV™ technology, which is now designed to allow patients to safely undergo magnetic resonance imaging (MRI). The Prometra II system is labeled as MR-Conditional and can safely undergo such scans providing specific conditions are followed. These specific steps are described in the Instructions for Use supplied with the product.

Over 100 million Americans suffer from some form of chronic pain caused by injury or disease, and in some cases the pain is severe enough that it interferes with the person's ability to work or lead a normal life. For such individuals, conventional pharmacological therapy or other pain strategies are often insufficient to control their pain. Implantable intrathecal drug delivery systems help alleviate pain by continuously and/or periodically delivering pain medicine directly into the intrathecal space or spinal fluid. Pain relief can be obtained with much lower total daily dosages of pain medication than conventional oral drug therapy.

"We realize this is an important milestone in the therapy for this patient, but it is also an important milestone for us, as this is the first implant of the Prometra II system in Danbury, CT," stated Steven Adler, President and CEO of Flowonix. "Our goal at Flowonix is to provide doctors and their patients all over the world with the most accurate, innovative, and reliable intrathecal infusion systems available. We congratulate David Kloth, MD, on the first implant of the Prometra II in Danbury, CT, and we wish all the best to the patient."

About Flowonix
Flowonix Medical Inc. (www.flowonix.com), headquartered in Mt. Olive, NJ, is dedicated to working with healthcare professionals to help ease suffering associated with chronic pain and allow patients to reclaim their lives through innovation and therapy advancements. The strategic business goal of Flowonix Medical Inc. is to become the leading implantable drug delivery company in the world. Founded in 2005, Flowonix Medical Inc. received approval to conduct its first clinical trial in 2007 on the Prometra programmable implantable pump. The company received approval by the FDA to market the Prometra in 2012. Flowonix Medical Inc. has been granted multiple patents, and is focused on working closely with physicians to rapidly improve the capabilities of implantable drug delivery and management systems.    
For more information, please visit http://www.flowonix.com.  

About Dr. David Kloth
Dr. Kloth is the President and Medical Director of Connecticut Pain Care with offices located in Danbury and New Canaan Connecticut. Connecticut Pain Care's mission is to provide high quality, compassionate, state of the art medical care which helps alleviate chronic pain and restore patient function. Dr. Kloth is also the current President of the North American Neuromodulation Society.

Connecticut Pain Care
100 Mill Plain Rd.
Danbury, CT 06811
Phone: (203) 792-7246 
(203) 792-9636 

Logo - http://photos.prnewswire.com/prnh/20150627/226378LOGO

SOURCE Flowonix Medical Inc.